Daniel Gesua Sive Salvadori - Dec 23, 2021 Form 4 Insider Report for ABBOTT LABORATORIES (ABT)

Role
EXECUTIVE VICE PRESIDENT
Signature
/s/ Daniel Gesua Sive Salvadori by Jessica H. Paik, Attorney-in-Fact
Stock symbol
ABT
Transactions as of
Dec 23, 2021
Transactions value $
-$5,890,766
Form type
4
Date filed
12/28/2021, 04:20 PM
Previous filing
Dec 15, 2021
Next filing
Feb 23, 2022

Transactions Table

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Ownership Footnotes
transaction ABT Common shares without par value Options Exercise $913K +23.8K +22.87% $38.40 128K Dec 23, 2021 Direct
transaction ABT Common shares without par value Options Exercise $1.39M +31.2K +24.45% $44.40 159K Dec 23, 2021 Direct
transaction ABT Common shares without par value Sale -$8.19M -58.5K -36.81% $140.00 100K Dec 23, 2021 Direct

Derivative Securities (e.g., puts, calls, warrants, options, convertible securities)

Type Sym Class Transaction Value $ Shares Change % * Price $ Shares After Date Underlying Class Amount Exercise Price Ownership Footnotes
transaction ABT Option (right to buy) Options Exercise $0 -23.8K -50% $0.00 23.8K Dec 23, 2021 Common Shares 23.8K $38.40 Direct F1
transaction ABT Option (right to buy) Options Exercise $0 -31.2K -29.24% $0.00 75.6K Dec 23, 2021 Common Shares 31.2K $44.40 Direct F1
* An asterisk sign (*) next to the price indicates that the price is likely invalid.

Explanation of Responses:

Id Content
F1 Employee stock option granted pursuant to the Abbott Laboratories 2009 Incentive Stock Program, in a transaction exempt from Section 16 under Rule 16b-3.

Remarks:

These transactions were made pursuant to a previously adopted plan complying with Rule 10b5-1(c).